Arcturus Therapeutics
ARCT
164 hedge funds and large institutions have $609M invested in Arcturus Therapeutics in 2024 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 58 increasing their positions, 49 reducing their positions, and 30 closing their positions.
45% more call options, than puts
Call options by funds: $5.34M | Put options by funds: $3.68M
18% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 49
0.51% less ownership
Funds ownership: 97.61% → 97.1% (-0.51%)
5% less capital invested
Capital invested by funds: $640M → $609M (-$30.8M)
4% less funds holding
Funds holding: 171 → 164 (-7)
23% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NAMA
Nikko Asset Management Americas
New York
|
+$16.1M |
| 2 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$15.2M |
| 3 |
BlackRock
New York
|
+$6.46M |
| 4 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$4.7M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$11.3M |
| 2 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$7.61M |
| 3 |
Millennium Management
New York
|
-$6.82M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.95M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$5.66M |
ARCT Hedge Fund Activity: Q3 2024 in Review
164 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q3 2024, worth a combined $609M — down 4.8% from $640M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of ARCT and 23 opened new positions — a net loss of 7 holders — while 49 trimmed existing stakes and 58 added.
The largest buyer was Nikko Asset Management Americas, adding an estimated $16.1M. The largest seller was Morgan Stanley, cutting an estimated $11.3M.
- 164 institutional investors held Arcturus Therapeutics (ARCT) as of Q3 2024, down from 171 in Q2 2024.
- Funds reported $609M of Arcturus Therapeutics stock for Q3 2024, down 4.8% quarter-over-quarter.
- 23 funds opened new Arcturus Therapeutics positions in Q3 2024 and 30 closed out, a net change of -7 holders.
- The largest Arcturus Therapeutics buyer in Q3 2024 was Nikko Asset Management Americas, an estimated $16.1M added.
- The largest Arcturus Therapeutics seller in Q3 2024 was Morgan Stanley, an estimated $11.3M sold.
Based on aggregated 13F filings for Q3 2024.